AFC
CRNX icon

Ares Financial Consulting’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ares Financial Consulting’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449 Hold
12
– – ﹤0.01% 1091
2026
Q1 		$439 Hold
12
– – ﹤0.01% 1022
2025
Q4 		$559 Buy
+12
New +$534 ﹤0.01% 843

Other funds holding CRNX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Ares Financial Consulting's CRNX Position: Q2 2026 in Review

Ares Financial Consulting held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 12 shares worth $449. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Ares Financial Consulting first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $559 in Q4 2025. 73 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Ares Financial Consulting held 12 shares of Crinetics Pharmaceuticals worth $449 as of Q2 2026.
  • Ares Financial Consulting left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1091 holding.
  • Ares Financial Consulting first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ares Financial Consulting's Crinetics Pharmaceuticals position peaked at $559 in Q4 2025.
  • 73 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.